Increased GFAp levels in CSF as a marker of organicity in patients with Alzheimer's disease and other types of irreversible chronic organic brain syndrome
- PMID: 3522811
- DOI: 10.1007/BF00314423
Increased GFAp levels in CSF as a marker of organicity in patients with Alzheimer's disease and other types of irreversible chronic organic brain syndrome
Abstract
Glial fibrillary acidic protein (GFAp), an astrocyte-specific protein, was determined in cerebrospinal fluid (CSF) of adults and children with global cognitive dysfunction. In children CSF-GFAp values were not closely associated with organic brain disease. However, GFAp values in CSF were increased in 65 of 121 samples of adults with dementia, independent of its cause. GFAp values were not correlated with the severity of the dementia. Increased levels in the CSF are believed to indicate reactive gliosis in most patients with dementia, whereas GFAp levels in encephalitic patients normalize after clinical recovery.
Similar articles
-
Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease.J Alzheimers Dis. 2009;17(3):541-51. doi: 10.3233/JAD-2009-1075. J Alzheimers Dis. 2009. PMID: 19433893
-
Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.J Neurochem. 2016 Jan;136(2):258-61. doi: 10.1111/jnc.13399. Epub 2015 Nov 11. J Neurochem. 2016. PMID: 26485083
-
The cerebrospinal fluid level of glial fibrillary acidic protein is increased in cerebrospinal fluid from Alzheimer's disease patients and correlates with severity of dementia.Eur Neurol. 2001;46(1):35-8. doi: 10.1159/000050753. Eur Neurol. 2001. PMID: 11455181
-
Blood and cerebrospinal fluid anomalies in brain ageing and Alzheimer's disease.Gerontology. 1987;33(3-4):193-6. doi: 10.1159/000212875. Gerontology. 1987. PMID: 2443427
-
Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases.Ann Clin Biochem. 2003 Jan;40(Pt 1):25-40. doi: 10.1258/000456303321016141. Ann Clin Biochem. 2003. PMID: 12542908 Review.
Cited by
-
TNF alpha affects the expression of GFAP and S100B: implications for Alzheimer's disease.J Neural Transm (Vienna). 2006 Nov;113(11):1709-15. doi: 10.1007/s00702-006-0479-5. Epub 2006 Jun 1. J Neural Transm (Vienna). 2006. PMID: 16736247
-
Integrated Genomic, Transcriptomic and Proteomic Analysis for Identifying Markers of Alzheimer's Disease.Diagnostics (Basel). 2021 Dec 8;11(12):2303. doi: 10.3390/diagnostics11122303. Diagnostics (Basel). 2021. PMID: 34943540 Free PMC article.
-
Inflammatory aspects of Alzheimer's disease.Acta Neuropathol. 2024 Aug 28;148(1):31. doi: 10.1007/s00401-024-02790-2. Acta Neuropathol. 2024. PMID: 39196440 Review.
-
Neuroimmunotoxicology: humoral assessment of neurotoxicity and autoimmune mechanisms.Environ Health Perspect. 1999 Oct;107 Suppl 5(Suppl 5):767-75. doi: 10.1289/ehp.99107s5767. Environ Health Perspect. 1999. PMID: 10502543 Free PMC article. Review.
-
Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?Eur Arch Psychiatry Clin Neurosci. 2012 Aug;262(5):375-91. doi: 10.1007/s00406-011-0280-9. Epub 2011 Dec 16. Eur Arch Psychiatry Clin Neurosci. 2012. PMID: 22173848 Review.
References
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous